Background {#Sec1}
==========

Polycystic ovary syndrome (PCOS), featured by oligomenorrhea, polycystic ovaries, anovulatory infertility, hyperandrogenism, insulin resistance or hyperinsulinemia, and an elevated risk of multiple metabolic diseases, is an extremely common reproductive endocrine disorder, with an estimated prevalence of approximately 5--10% in women of childbearing age \[[@CR1]--[@CR3]\]. Although the exact cause of PCOS remains unclear, mounting evidence supports that genetic factors play vital roles in its pathogenesis. First, family clustering of PCOS was not uncommon, and first-degree relatives of PCOS patients suffered an increased risk of developing PCOS and its associated disorders \[[@CR4], [@CR5]\]. Second, various genetic variants were found to be correlated with a higher PCOS risk \[[@CR6]\]. However, PCOS is a highly heterogeneous disorder and genetic determinants underlying PCOS are still poorly understood \[[@CR7], [@CR8]\].

Adiponectin (ADIPOQ), a multifunctional adipocytokine that is primarily secreted by adipocytes, plays a pivotal role in regulating energy and material metabolism \[[@CR9]\]. Previous studies showed that expression level of adiponectin was significantly reduced in patients with various metabolic disorders such as diabetes, obesity and insulin resistance, which suggested that adipoenctin might be involved in the pathogenesis of above-mentioned diseases \[[@CR10], [@CR11]\]. Considering the metabolic nature of PCOS and the fact that the expression levels of adiponectin and its receptors in female reproductive organs (ovary and uterus) vary in different phases of oestrous cycle \[[@CR12]\], it is biologically plausible that adiponectin might also be implicated in the occurrence and development of PCOS.

Adiponectin is encoded by the *ADIPOQ* gene located on chromosome 3q27 \[[@CR13]\]. It was evident that two common functional *ADIPOQ* polymorphisms, rs1501299 and rs2241766, were correlated with altered serum concentration of adiponectin \[[@CR14], [@CR15]\]. As a result, these two polymorphisms were thought to be ideal genetic biomarkers of multiple metabolic disorders including PCOS. So far, several studies already investigated associations between these *ADIPOQ* polymorphisms and PCOS risk, but the results of these studies were controversial \[[@CR16]--[@CR33]\]. Therefore, we performed the present meta-analysis to better explore potential roles of *ADIPOQ* polymorphisms in PCOS.

Methods {#Sec2}
=======

Literature search and inclusion criteria {#Sec3}
----------------------------------------

This meta-analysis was adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline \[[@CR34]\]. Potentially related literatures (published before September 2018) were retrieved from PubMed, Medline and Embase using the following searching strategy: (adiponectin OR ADIPOQ) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (polycystic ovary syndrome OR PCOS). Furthermore, the references of retrieved articles were also screened for other potentially relevant studies.

To test the research hypothesis of this meta-analysis, included studies must meet all the following criteria: (1) case-control study on correlations between *ADIPOQ* polymorphisms and PCOS risk; (2) provide genotypic and/or allelic frequency of investigated *ADIPOQ* polymorphisms in cases and controls; (3) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to *ADIPOQ* polymorphisms and PCOS; (2) case reports or case series; (3) abstracts, reviews, comments, letters and conference presentations. For duplicate publications, we only included the study with the largest sample size for analyses.

Data extraction and quality assessment {#Sec4}
--------------------------------------

The following data were extracted from included studies: (1) the name of the first author; (2) publication time; (3) country and ethnicity; (4) sample size; and (5) genotypic distributions of *ADIPOQ* polymorphisms in cases and controls. Additionally, the probability value (*p* value) of Hardy-Weinberg equilibrium (HWE) was also calculated. When necessary, we wrote to the corresponding authors for raw data. We used the Newcastle-Ottawa scale (NOS) to assess the quality of eligible studies \[[@CR35]\]. This scale has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analysis {#Sec5}
--------------------

All statistical analyses were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate strength of associations between *ADIPOQ* polymorphisms and PCOS risk in all possible genetic models, and *p* values ≤0.05 were considered to be statistically significant. Between-study heterogeneities were evaluated with I^2^ statistic. If I^2^ was greater than 50 %, random-effect models (REMs) would be used to pool the data. Otherwise, fixed-effect models (FEMs) would be employed for synthetic analyses. Subgroup analyses by ethnicity were subsequently performed. Sensitivity analyses were conducted to examine the stability of synthetic results. Funnel plots were used to evaluate possible publication bias.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

We found 331 potential relevant articles. Among these articles, a total of 18 eligible studies were finally included for synthetic analyses (see Fig. [1](#Fig1){ref-type="fig"}). The NOS score of eligible articles ranged from 7 to 8, which indicated that all included studies were of high quality. Baseline characteristics of included studies were shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Flowchart of study selection for the present studyTable 1The characteristics of included studiesFirst author, yearCountryEthnicityAge (years)\
Case/ControlSample sizeGenotype distribution*P*-value for HWENOS scoreCases Controls**rs1501299 G/T**GG/GT/TTGG/GT/TT Alfaqih 2018 \[[@CR16]\]JordonWest Asian23.9/24.2154/15162/77/1564/54/330.0028 Czeczuga-Semeniuk 2018 \[[@CR17]\]PolandCaucasian24.6/23.2294/78156/117/2125/49/40.0028 Escobar-Morreale 2006 \[[@CR19]\]SpainCaucasianNA76/4030/39/715/21/40.3907 Heinonen 2005 \[[@CR21]\]FinlandCaucasianNA143/24577/58/8110/110/250.7447 Li 2011 \[[@CR22]\]KoreaEast AsianNA144/15961/73/1048/87/240.1317 Nambiar 2016 \[[@CR23]\]IndiaWest Asian28.6/31.1282/20094/165/2386/99/150.0608 Pau 2013 \[[@CR25]\]USAMixedNA525/472NANANA7 Radavelli-Bagatini 2013 \[[@CR26]\]BrazilMixedNA80/150042/27/11671/672/1570.5567 Ramezani Tehrani 2013 \[[@CR27]\]IranWest Asian26.6/30.8186/15692/76/1877/71/80.1007 Ranjzad 2012 \[[@CR28]\]IranWest Asian27.1/31.1181/18192/77/1291/79/110.2548 San Millán 2004 \[[@CR29]\]SpainCaucasian24.6/31.172/4228/34/1018/20/40.6437 Xita 2005 \[[@CR30]\]GreeceCaucasian23.7/24.8100/14039/49/1252/73/150.1527 Yoshihara 2009 \[[@CR31]\]JapanEast Asian29.1/29.838/9719/15/458/24/15\< 0.0018 Zhang 2008 \[[@CR32]\]ChinaEast Asian28.7/29.6120/12056/46/1841/50/290.0838 Zhang 2015 \[[@CR33]\]ChinaEast Asian27.0/27.2207/192119/78/1095/75/220.2297**rs2241766 T/G**TT/TG/GGTT/TG/GG Alfaqih 2018 \[[@CR16]\]JordonWest Asian23.9/24.2154/14992/48/1493/42/140.0088 Czeczuga-Semeniuk 2018 \[[@CR17]\]PolandCaucasian24.6/23.2294/78255/39/062/16/00.3138 Demirci 2010 \[[@CR18]\]TurkeyCaucasian24.1/23.896/9370/20/674/16/30.0918 Escobar-Morreale 2006 \[[@CR19]\]SpainCaucasianNA76/4055/20/126/13/10.6737 Haap 2005 \[[@CR20]\]GermanyCaucasian27.4/38.953/54238/8/7414/112/160.0168 Heinonen 2005 \[[@CR21]\]FinlandCaucasianNA143/245125/17/1222/22/10.5727 Li 2011 \[[@CR22]\]KoreaEast AsianNA144/15979/59/672/84/3\< 0.0017 Nambiar 2016 \[[@CR23]\]IndiaWest Asian28.6/31.1282/200213/60/9156/40/40.4538 Panidis 2004 \[[@CR24]\]GreeceCaucasian23.4/29.4132/10092/33/781/17/20.3407 Radavelli-Bagatini 2013 \[[@CR26]\]BrazilMixedNA80/150064/14/21122/356/220.2977 Ramezani Tehrani 2013 \[[@CR27]\]IranWest Asian26.6/30.8186/156142/42/2106/46/40.7077 Ranjzad 2012 \[[@CR28]\]IranWest Asian27.1/31.1181/181144/34/2121/54/60.9938 San Millán 2004 \[[@CR29]\]SpainCaucasian24.6/31.172/4248/22/229/12/10.8537 Xita 2005 \[[@CR30]\]GreeceCaucasian23.7/24.8100/14077/23/0106/30/40.3067 Yoshihara 2009 \[[@CR31]\]JapanEast Asian29.1/29.838/9719/19/053/29/150.0048 Zhang 2008 \[[@CR32]\]ChinaEast Asian28.7/29.6120/12057/54/974/42/40.5048 Zhang 2015 \[[@CR33]\]ChinaEast Asian27.0/27.2207/192106/84/1798/75/190.4097*PCOS* Polycystic ovary syndrome, *HWE* Hardy-Weinberg equilibrium, *NOS* Newcastle-Ottawa scale, *NA* Not available

Overall and subgroup analyses {#Sec8}
-----------------------------

To investigate potential correlations between *ADIPOQ* polymorphisms and PCOS risk, fifteen studies about rs1501299 polymorphism and seventeen studies about rs2241766 polymorphism were included for pooled analyses. A significant association with PCOS risk was detected for rs1501299 (recessive model: *p* = 0.02, OR = 0.77, 95%CI 0.62--0.95; allele model: *p* = 0.001, OR = 1.15, 95%CI 1.06--1.26) polymorphism in overall analyses. Further subgroup analyses according to ethnicity of participants revealed that rs1501299 and rs2241766 polymorphisms were both significantly correlated with PCOS risk in Caucasians. In addition, rs1501299 polymorphism was also significantly correlated with PCOS risk in East Asians (see Table [2](#Tab2){ref-type="table"}).Table 2Results of overall and subgroup analyses for *ADIPOQ* gene polymorphisms and PCOSPopulationSample sizeDominant comparisonRecessive comparisonAdditive comparisonAllele comparison*P* valueOR (95%CI)I^2^ statistic*P* valueOR (95%CI)I^2^ statistic*P* valueOR (95%CI)I^2^ statistic*P* valueOR (95%CI)I^2^ statistic**rs1501299 G/T**GG vs. GT + TTTT vs. GG + GTGT vs. GG + TTG vs. TOverall2602/37730.101.17 (0.97--1.42)52%**0.020.77 (0.62--0.95)**46%0.520.94 (0.76--1.15)58%**0.0011.15 (1.06--1.26)**43%Caucasian685/545**0.0071.40 (1.09--1.79)**42%0.790.94 (0.62--1.45)0%**0.010.73 (0.58--0.93)**48%**0.031.22 (1.02--1.46)**22%East Asian509/568**0.0061.41 (1.10--1.81)**37%**0.00030.48 (0.32--0.71)**0%0.760.96 (0.75--1.23)17%**0.00011.44 (1.20--1.73)**2%West Asian803/6880.190.87 (0.71--1.07)4%0.880.95 (0.47--1.89)70%0.301.19 (0.85--1.68)62%0.520.95 (0.81--1.11)31%**rs2241766 T/G**TT vs. TG + GGGG vs. TT + TGTG vs. TT + GGT vs. GOverall2358/40340.631.03 (0.91--1.18)46%0.541.10 (0.81--1.50)41%0.440.95 (0.83--1.09)44%1.001.00 (0.84--1.19)54%Caucasian966/12800.320.89 (0.70--1.12)22%**0.041.93 (1.05--3.56)**26%0.841.03 (0.80--1.31)6%0.110.84 (0.68--1.04)46%East Asian509/5680.740.93 (0.62--1.40)61%0.861.10 (0.40--3.02)59%0.541.17 (0.71--1.93)73%0.950.99 (0.73--1.35)58%West Asian803/6860.311.22 (0.83--1.80)65%0.560.85 (0.49--1.47)8%0.310.83 (0.59--1.18)53%0.321.19 (0.84--1.69)67%*OR* Odds ratio, *CI* Confidence interval, *NA* Not available. *PCOS* Polycystic ovary syndromeThe values in bold represent there is statistically significant differences between cases and controls

Sensitivity analyses {#Sec9}
--------------------

We performed sensitivity analyses by excluding studies that deviated from HWE. No alterations of results were detected in sensitivity analyses, which suggested that our findings were statistically reliable.

Publication biases {#Sec10}
------------------

Publication biases were evaluated with funnel plots. We did not find obvious asymmetry of funnel plots in any comparisons, which indicated that our findings were unlikely to be impacted by severe publication biases.

Discussion {#Sec11}
==========

To the best of our knowledge, this is so far the most comprehensive meta-analysis on correlations between *ADIPOQ* polymorphisms and PCOS risk. Our overall and subgroup analyses demonstrated that rs1501299 and rs2241766 polymorphisms were both significantly correlated with PCOS risk in Caucasians. Moreover, rs1501299 polymorphism was also significantly correlated with PCOS risk in East Asians.

There are several points that need to be addressed about this meta-analysis. Firstly, previous experimental studies showed that mutant alleles of investigated polymorphisms were correlated with decreased adiponectin generation, which may partially explain our positive findings \[[@CR14], [@CR15]\]. Secondly, the pathogenic mechanism of PCOS is highly complex, and hence it is unlikely that a single gene polymorphism could significantly contribute to its development. As a result, to better illustrate potential correlations of certain gene polymorphisms with PCOS, we strongly recommend further studies to perform haplotype analyses and explore potential gene-gene interactions.

As with all meta-analysis, this study certainly has some limitations. First, our results were derived from unadjusted analyses due to lack of raw data, and lack of further adjusted analyses for potential confounding factors may impact the reliability of our findings \[[@CR36]\]. Second, obvious heterogeneities were found in several subgroups, which indicated that the controversial results of included studies could not be fully explained by differences in ethnic background, and other baseline characteristics of participants may also contribute to between-study heterogeneities \[[@CR37]\]. Third, associations between *ADIPOQ* polymorphisms and PCOS risk may also be modified by gene-gene and gene-environmental interactions. However, most eligible studies ignore these potential interactions, which impeded us to perform relevant analyses accordingly \[[@CR38]\]. To sum up, our findings should be cautiously interpreted on account of above mentioned limitations.

Conclusions {#Sec12}
===========

In conclusion, our meta-analysis suggested that rs1501299 and rs2241766 polymorphisms might serve as genetic biomarkers of PCOS in certain ethnicities. However, further well-designed studies are still warranted to confirm our findings.
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